Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) EBIT (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed EBIT for 9 consecutive years, with -$8.6 million as the latest value for Q4 2025.

  • On a quarterly basis, EBIT rose 40.21% to -$8.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $23.5 million, a 146.56% increase, with the full-year FY2025 number at $23.5 million, up 146.56% from a year prior.
  • EBIT was -$8.6 million for Q4 2025 at Akebia Therapeutics, down from $4.4 million in the prior quarter.
  • In the past five years, EBIT ranged from a high of $34.1 million in Q2 2022 to a low of -$79.3 million in Q2 2021.
  • A 5-year average of -$20.9 million and a median of -$12.8 million in 2023 define the central range for EBIT.
  • Peak YoY movement for EBIT: tumbled 1141.19% in 2024, then skyrocketed 261.48% in 2025.
  • Akebia Therapeutics' EBIT stood at -$65.3 million in 2021, then surged by 92.55% to -$4.9 million in 2022, then soared by 128.23% to $1.4 million in 2023, then crashed by 1141.19% to -$14.3 million in 2024, then surged by 40.21% to -$8.6 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's EBIT are -$8.6 million (Q4 2025), $4.4 million (Q3 2025), and $14.1 million (Q2 2025).